New Illinois bill would allow mothers paid breaks to breastfeed
The , sponsored by Illinois Senator Laura Fine (D-Glenview), were first read in Illinois' General Assembly on January 22nd.
The Nursing Mothers in the Workplace Act would be changed to require employers to provide 30 minutes of paid breaks to mothers who need to breastfeed or pump.
'When you're a new mom and you're tired, you're emotional and you're getting back to work, for me we did not have that break to take care of my child,' Fine said.
These required breaks would not cut into any other required breaks.
Fine explained she wants to look out for succeeding generations by implementing these new requirements.
'We want to make [it] easier and smoother for future generations,' said Fine. 'Women causes are front and center cause we're saying that this is what impacted us, how can we improve it for future generations.'
Senator Doris Turner (D-Springfield) stands with Fine on these issues and has sponsored a of her own to introduce a plan to cover hypoallergenic formula under Medicaid if it has been prescribed by a physician.
'You can imagine the strain that would put on your budget,' Turner said. 'We are ensuring that families get a fair chance at a healthy life regardless of their income.'
Both bills have been sent to committee and could be deliberated later in February.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hill
2 hours ago
- The Hill
Memo pushes back on bill's impact to rural hospitals
A new memo shared first with The Hill argues the law 'contains unprecedented levels of federal assistance to rural and other vulnerable hospitals' through its five-year, $50 billion Rural Health Transformation Program. The administration notes that Medicaid has historically invested very little in rural hospitals. According to figures from the Centers for Medicare and Medicaid Services (CMS), Medicaid spent just $19 billion on rural hospitals in 2024. The rural health fund will provide an additional $10 billion each year from 2026 through 2030. But it ends after 2030, with no phaseout period. The memo argues the fund is a 'flexible' source of investment because it's not tied directly to reimbursement for services. Indeed, as experts have noted, the fund will not make direct payments to rural hospitals. Instead, the money will go to states, which will need to first file detailed 'rural health transformation plans' and get approval from CMS Administrator Mehmet Oz. The law gives Oz broad discretion on what he can approve, and there is no specific requirement for states to direct funds to rural hospitals or CMS to approve only funding for rural districts. States also need to make funding decisions quickly, as the federal government can claw back unobligated money before the program ends. The new law cuts about $1 trillion from Medicaid, primarily through stringent work requirements as well as reductions to how states can fund their Medicaid programs through provider taxes and state-directed payments. Rural hospitals rely heavily on Medicaid funding because many of the patients they care for are low income. But the administration noted that rural hospitals only account for 7 percent of overall Medicaid spending. According to a KFF analysis, federal Medicaid spending in rural areas is estimated to decline by $155 billion over a decade because of the law.
Business Wire
4 hours ago
- Business Wire
Delcath Systems to Host Second Quarter 2025 Earnings Call
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on August 6, 2025, at 8:30 AM Eastern Time to discuss results for its second quarter ended June 30, 2025. Conference Call Information To participate in this event, dial in approximately 5 to 10 minutes before the beginning of the call. Participant Numbers: Toll Free: 1-877-407-3982 International: 1-201-493-6780 Webcast: A replay of the webinar will be available shortly after the conclusion of the call and will be archived on the company's website here. About Delcath Systems, Inc., HEPZATO KIT and CHEMOSAT Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company's proprietary products, HEPZATO KIT™ (Hepzato (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT ® Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. In the United States, HEPZATO KIT is considered a combination drug and device product and is regulated and approved for sale as a drug by the FDA. HEPZATO KIT is comprised of the chemotherapeutic drug melphalan and Delcath's proprietary Hepatic Delivery System (HDS). The HDS is used to surgically isolate the liver while simultaneously filtrating hepatic venous blood during melphalan infusion and washout. The use of the HDS results in loco-regional delivery of a relatively high melphalan dose, which can potentially induce a clinically meaningful tumor response with minimal hepatotoxicity and reduce systemic exposure. HEPZATO KIT is approved in the United States as a liver-directed treatment for adult patients with metastatic uveal melanoma (mUM) with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation. Please see the full Prescribing Information, including BOXED WARNING for the HEPZATO KIT. In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has been used in the conduct of percutaneous hepatic perfusion procedures at major medical centers to treat a wide range of cancers of the liver.
The Hill
5 hours ago
- The Hill
Missouri AG sues Planned Parenthood for allegedly lying about dangers of abortion drugs
Missouri is suing Planned Parenthood for allegedly lying to patients about the risks of the abortion medication mifepristone. Missouri Attorney General Andrew Bailey (R) filed a lawsuit Wednesday in Jefferson City arguing that Planned Parenthood's claims that the abortion drug is safer than many other medications including penicillin and Tylenol are untrue and violate the state's consumer-protection law. Bailey claims that the nonprofit organization has lied about the safety of the drug to 'cut costs and boost revenue,' according to the lawsuit. The complaint also requests a court order to stop Planned Parenthood from 'continuing to promote the falsehoods,' in Missouri and for the organization to pay more than $1.8 million in civil penalties. The attorney general's office is also asking for the organization to be fined $1,000 in damages to every woman in the Show-Me State that has received abortion medication through one of is providers in the past five years. On top of this, it asks that the organization reimburse the state for Medicaid and other tax-payer-funded emergency care provided to people who suffered complications after taking mifepristone. 'We are going to hold these charlatans and death dealers accountable,' Bailey wrote in a post on social platform X about the suit. The crux of the lawsuit's argument comes down to a disagreement over how many people suffer adverse health effects after taking mifepristone. On the Food and Drug Administration's (FDA) warning label for the drug, it states that between 2.9 percent and 4.6 percent of people who have taken it along with misoprostol report visiting an emergency room afterwards. There are two drugs typically needed for a medication abortion: mifepristone and misoprostol. Mifepristone stops the pregnancy from growing while misoprostol induces cramping and bleeding to empty the uterus. More than 100 scientific studies across decades have looked at the efficacy and safety of the pair and all of them have found the drugs safe for use, according to an analysis from The New York Times. Bailey's lawsuit claims that the FDA's label is inaccurate and that 'recent studies' suggest the complication rate is much higher. The lawsuit does not cite a specific study to back up its claim and a spokesperson for the attorney general's office did not answer questions from The Hill about what data was used to back up its claim. The lawsuit does echo findings outlined in a deeply flawed study published in April by the conservative think tank the Ethics and Public Policy Center (EPPC) which states that after analyzing more than 865,000 prescribed mifepristone abortions, it determined that nearly 11 percent of women experienced a 'serious adverse event.' That's nearly 22 times higher than what the FDA reports. Bailey's lawsuit references a 'dataset' of more than 850,000 mifepristone abortions that identified 'serious adverse events' in more than 10 percent of women who took the drug. Medical researchers have criticized the EPPC study for its lack of transparency and for flaws in its methodology. One of the largest hiccups of the study is its inclusion of emergency room visits as one of the 'serious adverse events' that can happen after taking the abortion pill, health experts say. The EPPC study breaks down 'serious adverse events' into categories including hemorrhage, sepsis and emergency room visits. It looks as if emergency room visits were counted as adverse events even if health care workers determined the patient was healthy and released them without treatment. Some people might go to an emergency room after taking the abortion pill to confirm that they are no longer pregnant or to make sure that the bleeding they are experiencing is normal, two principal research scientists at the Guttmacher Institute noted in an op-ed last month. The lawsuit is the latest attack from conservative lawmakers on Planned Parenthood. Under the GOP's new tax and spending bill, the organization would lose its ability to receive Medicaid reimbursements for health services it provides for one year. The nonprofit sued the Trump administration over the provision and a federal judge granted the organization's request for a temporary injunction earlier this week.
